Meta Biomed Co., Ltd.

As of March 31, 2026, Meta Biomed Co., Ltd. carries a market capitalization of 112.90B, placing it among publicly traded companies globally. Its enterprise value stands at 119.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Meta Biomed Co., Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Meta Biomed Co., Ltd. has 27.17M shares outstanding.

As of March 31, 2026, Meta Biomed Co., Ltd. trades at a trailing price-to-earnings ratio of 11.13. The price-to-sales ratio is 1.09, and the price-to-book ratio stands at 0.89.

As of March 31, 2026, Meta Biomed Co., Ltd. trades at an EV/EBITDA multiple of 4.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.20 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Meta Biomed Co., Ltd. trades at an EV/FCF ratio of 290.20, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 119.81B versus a market cap of 112.90B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Meta Biomed Co., Ltd. maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.57, indicating elevated leverage, while an interest coverage ratio of 11.22 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Meta Biomed Co., Ltd. posted a return on equity (ROE) of 8.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.31, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.32, useful for judging operating efficiency across full business cycles. The company generates approximately 310.99M in revenue per employee across its workforce of 320.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.25 indicates how many times Meta Biomed Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Meta Biomed Co., Ltd. recorded 1.84B in income tax expense. That works out to an effective tax rate of 16.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.36B, leaving 9.78B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Meta Biomed Co., Ltd.'s stock has declined approximately 38.36% over the past 52 weeks. The 50-day moving average sits at 3,846.20, while the 200-day moving average is 4,190.65.

Over the twelve months ended March 31, 2026, Meta Biomed Co., Ltd. generated 99.67B in revenue and converted that into 9.78B in net income, yielding earnings per share of 352.94. EBITDA reached 26.40B, while operating income came in at 20.67B.

As of March 31, 2026, Meta Biomed Co., Ltd. holds 37.75B in cash and equivalents against 44.24B in total debt, resulting in a net debt position of 26.59B. Total book value stands at 127.52B, with working capital of 29.98B providing operational flexibility.

Meta Biomed Co., Ltd. produced 17.06B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -18.62B in capital expenditures, free cash flow totaled -1.56B - equivalent to -59.52 per share.

Over the twelve months ended March 31, 2026, Meta Biomed Co., Ltd. posted a gross margin of 53.55, reflecting its pricing power and cost economics. The operating margin of 20.73 and net profit margin of 9.81 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Meta Biomed Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 6.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Meta Biomed Co., Ltd. shareholders.

Meta Biomed Co., Ltd.'s most recent stock split took place on April 23, 2010 with a 1:2 split ratio.

As of March 31, 2026, Meta Biomed Co., Ltd. has an Altman Z-Score of 2.60, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.